Investor Relations

OPKO Health to Present at the Jefferies 2013 Global Healthcare Conference more »

OPKO Surpasses 50% Enrollment in First Phase 3 Trial of RayaldyTM (CTAP101 Capsules) more »

OPKO Announces First Quarter 2013 Operating and Financial Highlights more »

OPKO Health To Acquire PROLOR Biotech more »

Investor FAQs